Femasys logo

FemasysNASDAQ: FEMY

Profile

Sector:

Healthcare

Country:

United States

IPO:

18 June 2021

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$22.44 M
-64%vs. 3y high
26%vs. sector
-vs. 3y high
-vs. sector
-38%vs. 3y high
74%vs. sector
-69%vs. 3y high
84%vs. sector

Price

after hours | Wed, 20 Nov 2024 00:58:40 GMT
$0.98$0.00(0.00%)

Dividend

No data over the past 3 years
$554.90 K$1.77 M
$554.90 K-$5.41 M

Analysts recommendations

Institutional Ownership

FEMY Latest News

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
globenewswire.com12 November 2024 Sentiment: POSITIVE

Company accelerated commercialization with significant new partnerships both in the U.S. and Europe Company accelerated commercialization with significant new partnerships both in the U.S. and Europe

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
globenewswire.com01 November 2024 Sentiment: POSITIVE

FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program
globenewswire.com10 October 2024 Sentiment: POSITIVE

Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
globenewswire.com02 October 2024 Sentiment: POSITIVE

ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribution partners after successfully completing its first commercial FemaSeed® procedures in Europe. Members of the Femasys team traveled to Madrid to in-service healthcare practitioners on the innovative FemaSeed infertility treatment, designed to enhance natural fertilization by precisely delivering sperm into the fallopian tube where conception occurs.

Femasys Announces Infertility Clinic Customers from Coast to Coast
globenewswire.com18 September 2024 Sentiment: POSITIVE

Leading medical clinics become key regional resources to offer FemaSeed infertility treatment Leading medical clinics become key regional resources to offer FemaSeed infertility treatment

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
globenewswire.com11 September 2024 Sentiment: POSITIVE

Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products

Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device
zacks.com10 September 2024 Sentiment: POSITIVE

FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
globenewswire.com09 September 2024 Sentiment: POSITIVE

In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting
globenewswire.com05 September 2024 Sentiment: POSITIVE

ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the Canadian Fertility and Andrology Society's (CFAS) 70th Annual Meeting, to be held September 12-14, 2024 at The Westin Bayshore, Vancouver, British Columbia. The Company will be exhibiting at Booth #S26.

Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI
zacks.com03 September 2024 Sentiment: POSITIVE

FEMY's eco-friendly FemVue MINI receives CE Mark and Health Canada approval, advancing sustainable fallopian tube assessment technology in Europe and Canada.

What type of business is Femasys?

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

What sector is Femasys in?

Femasys is in the Healthcare sector

What industry is Femasys in?

Femasys is in the Medical Instruments & Supplies industry

What country is Femasys from?

Femasys is headquartered in United States

When did Femasys go public?

Femasys initial public offering (IPO) was on 18 June 2021

What is Femasys website?

https://www.femasys.com

Is Femasys in the S&P 500?

No, Femasys is not included in the S&P 500 index

Is Femasys in the NASDAQ 100?

No, Femasys is not included in the NASDAQ 100 index

Is Femasys in the Dow Jones?

No, Femasys is not included in the Dow Jones index

When was Femasys the previous earnings report?

No data

When does Femasys earnings report?

The next expected earnings date for Femasys is 28 March 2025